Sutro Biopharma (STRO) Consolidated Net Income (2017 - 2025)
Historic Consolidated Net Income for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$56.9 million.
- Sutro Biopharma's Consolidated Net Income fell 1654.13% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$206.2 million, marking a year-over-year decrease of 6631.12%. This contributed to the annual value of -$227.5 million for FY2024, which is 11301.11% down from last year.
- Latest data reveals that Sutro Biopharma reported Consolidated Net Income of -$56.9 million as of Q3 2025, which was down 1654.13% from -$11.5 million recorded in Q2 2025.
- In the past 5 years, Sutro Biopharma's Consolidated Net Income registered a high of $31.1 million during Q4 2023, and its lowest value of -$72.5 million during Q4 2024.
- In the last 5 years, Sutro Biopharma's Consolidated Net Income had a median value of -$38.5 million in 2023 and averaged -$35.9 million.
- In the last 5 years, Sutro Biopharma's Consolidated Net Income surged by 18977.57% in 2023 and then crashed by 33337.73% in 2024.
- Sutro Biopharma's Consolidated Net Income (Quarter) stood at -$38.1 million in 2021, then increased by 9.26% to -$34.6 million in 2022, then surged by 189.78% to $31.1 million in 2023, then tumbled by 333.38% to -$72.5 million in 2024, then grew by 21.55% to -$56.9 million in 2025.
- Its last three reported values are -$56.9 million in Q3 2025, -$11.5 million for Q2 2025, and -$65.3 million during Q1 2025.